Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of IV Magnesium Sulfate on Fetal CTG in Preeclampsia
NCT03237000Phase 4
Key facts
- Status
- Unknown
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Countries
- 1
- Sponsor
- Cairo University
- Modality
- Small Molecules
- Drugs
- magnesium sulfate
- Conditions
- preeclampsia
01
Overview
Phase 4, open-label, single-arm trial of magnesium sulfate in preeclampsia, sponsored by Cairo University. Primary endpoint: Fetal heart rate tracing. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
MgSO4 Group
Patients receiving standard MgSO4 protocol for severe preeclampsia
03
Who it enrols
Pregnant women in the third trimester with severe preeclampsia and a normal admission CTG. Patients with fetal anomalies, concomitant maternal morbidities (diabetes, cardiac disease), advanced renal disease, abnormal admission CTG, or morbid obesity are excluded.
04
Endpoints
Primary
Fetal heart rate tracing
Beyond the preview
Go deeper on NCT03237000.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237000.